PortfoliosLab logoPortfoliosLab logo
MNPR vs. ^GSPC
Performance
Return for Risk
Drawdowns
Volatility

Performance

MNPR vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monopar Therapeutics Inc. (MNPR) and S&P 500 Index (^GSPC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MNPR achieves a 25.22% return, which is significantly higher than ^GSPC's 7.60% return.


MNPR

1D
19.09%
1M
29.55%
YTD
25.22%
6M
15.99%
1Y
156.90%
3Y*
165.89%
5Y*
20.30%
10Y*

^GSPC

1D
-1.44%
1M
-1.45%
YTD
7.60%
6M
6.59%
1Y
22.24%
3Y*
19.20%
5Y*
11.54%
10Y*
13.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MNPR vs. ^GSPC - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
MNPR
Monopar Therapeutics Inc.
25.22%196.82%1,193.36%-85.65%-26.17%-47.55%-63.13%98.80%
^GSPC
S&P 500 Index
7.60%16.39%23.31%24.23%-19.44%26.89%16.26%1.24%

Correlation

The correlation between MNPR and ^GSPC is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.29

Correlation (3Y)
Calculated over the trailing 3-year period

0.18

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (All Time)
Calculated using the full available price history since Dec 19, 2019

0.14

The correlation between MNPR and ^GSPC shifts across timeframes, from 0.14 (5 years) to 0.29 (1 year), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MNPR vs. ^GSPC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MNPR
MNPR Risk / Return Rank: 8484
Overall Rank
MNPR Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
MNPR Sortino Ratio Rank: 8686
Sortino Ratio Rank
MNPR Omega Ratio Rank: 8383
Omega Ratio Rank
MNPR Calmar Ratio Rank: 8484
Calmar Ratio Rank
MNPR Martin Ratio Rank: 7777
Martin Ratio Rank

^GSPC
^GSPC Risk / Return Rank: 6161
Overall Rank
^GSPC Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
^GSPC Sortino Ratio Rank: 5757
Sortino Ratio Rank
^GSPC Omega Ratio Rank: 6262
Omega Ratio Rank
^GSPC Calmar Ratio Rank: 5757
Calmar Ratio Rank
^GSPC Martin Ratio Rank: 7272
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MNPR vs. ^GSPC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and S&P 500 Index (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MNPR^GSPCDifference
Sharpe ratioReturn per unit of total volatility

+0.16

Sortino ratioReturn per unit of downside risk

+0.27

Omega ratioGain probability vs. loss probability

1.32

1.32

0.00

Calmar ratioReturn relative to maximum drawdown

3.10

2.46

+0.65

Martin ratioReturn relative to average drawdown

4.98

10.92

-5.93

MNPR vs. ^GSPC - Sharpe Ratio Comparison

The current MNPR Sharpe Ratio is 1.94, which is comparable to the ^GSPC Sharpe Ratio of 1.78. The chart below compares the historical Sharpe Ratios of MNPR and ^GSPC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MNPR vs. ^GSPC - Drawdown Comparison

The maximum MNPR drawdown since its inception was -98.93%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for MNPR and ^GSPC.


Loading charts...

Drawdown Indicators


MNPR^GSPCDifference

Max Drawdown

Largest peak-to-trough decline

-98.93%

-56.78%

-42.15%

Max Drawdown (1Y)

Largest decline over 1 year

-50.89%

-9.10%

-41.79%

Max Drawdown (3Y)

Largest decline over 3 years

-71.07%

-18.90%

-52.17%

Max Drawdown (5Y)

Largest decline over 5 years

-95.45%

-25.43%

-70.02%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-39.43%

-3.21%

-36.22%

Average Drawdown

Average peak-to-trough decline

-80.14%

-10.71%

-69.43%

Ulcer Index

Depth and duration of drawdowns from previous peaks

31.61%

2.04%

+29.57%

Volatility

MNPR vs. ^GSPC - Volatility Comparison

Monopar Therapeutics Inc. (MNPR) has a higher volatility of 19.63% compared to S&P 500 Index (^GSPC) at 4.89%. This indicates that MNPR's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MNPR^GSPCDifference

Volatility (1M)

Calculated over the trailing 1-month period

19.63%

4.89%

+14.74%

Volatility (6M)

Calculated over the trailing 6-month period

45.55%

9.93%

+35.62%

Volatility (1Y)

Calculated over the trailing 1-year period

81.51%

12.57%

+68.94%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

296.19%

17.00%

+279.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

277.36%

18.08%

+259.28%

Frequently Asked Questions


MNPR and ^GSPC have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MNPR has higher volatility (19.63%) compared to ^GSPC (4.89%). In terms of maximum drawdown, MNPR dropped -98.93% vs ^GSPC's -56.78%.

MNPR currently has the higher Sharpe Ratio (1.94 vs 1.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MNPR and ^GSPC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer